Gyre Therapeutics, Inc. (GYRE)Healthcare | Biotechnology | San Diego, United States | NasdaqCM
8.05 USD
+0.15
(1.913%)
⇧
(April 17, 2026, 10:23 a.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ★★★☆☆ | Dividends: ★☆☆☆☆ |
Hot Take | April 11, 2026, 3:10 p.m. EDT
GYRE is a high-risk, high-reward biotechnology stock with a significant beta and high overall risk. The recent price action shows volatility, with a recent uptick following news of acquisitions and regulatory filings. However, the stock's fundamentals are weak, with low profit margins and high price-to-earnings ratios, indicating potential overvaluation. The recent dividend history is inconsistent, and there are no recent dividends, which is a red flag for dividend investors. While the stock may benefit from upcoming events like the acquisition and regulatory submissions, the short-term forecast suggests a slight downward trend, and the long-term outlook is uncertain. Investors should be cautious and consider the high risk associated with this stock. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.058067 |
| AutoETS | 0.058728 |
| AutoTheta | 0.058751 |
| AutoARIMA | 0.062964 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 14.01 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.166 |
| Excess Kurtosis | -1.21 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Last Dividend Date | 2023-01-12 |
| Debt to Equity Ratio | 0.66 |
| Revenue per Share | 1.305 |
| Market Cap | 775,481,984 |
| Trailing P/E | 402.50 |
| Forward P/E | 134.17 |
| Beta | 6.40 |
| Profit Margins | 4.31% |
| Website | https://www.gyretx.com |
As of April 11, 2026, 3:10 p.m. EDT: The options data indicates a mixed sentiment. For calls, there is a notable amount of open interest (OI) in out-of-the-money (OTM) strikes, particularly for the April 17 expiration, suggesting some speculation on potential upward movement. However, the implied volatility (IV) is relatively low, which may indicate limited confidence or uncertainty about the stock's direction. On the puts side, there is higher OI in OTM strikes, especially for the April 17 expiration, with significant activity around lower strikes, implying some bearish sentiment or hedging against downside risk. The overall options activity does not strongly signal a clear direction, and the low IV for calls may suggest a lack of enthusiasm for aggressive price moves in either direction.
| Date | Dividend | Yield % |
|---|---|---|
| 2023-01-13 | 3.600 | 92.307690 |
| 2022-09-21 | 21.450 | 461.999959 |
| 2015-08-20 | 896.175 | 364.207197 |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.05952382 |
| Address1 | 12,770 High Bluff Drive |
| Address2 | Suite 150 |
| All Time High | 47,990.25 |
| All Time Low | 2.85 |
| Ask | 10.22 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 58,040 |
| Average Daily Volume3 Month | 98,249 |
| Average Volume | 98,249 |
| Average Volume10Days | 58,040 |
| Beta | 6.399 |
| Bid | 5.68 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 1.161 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.05 |
| Current Ratio | 5.598 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 8.1 |
| Day Low | 7.97 |
| Debt To Equity | 0.66 |
| Display Name | Gyre Therapeutics |
| Dividend Date | 1,673,481,600 |
| Earnings Timestamp | 1,773,318,600 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | 14,011,000 |
| Ebitda Margins | 0.120179996 |
| Enterprise To Ebitda | 50.399 |
| Enterprise To Revenue | 6.057 |
| Enterprise Value | 706,145,664 |
| Eps Forward | 0.06 |
| Eps Trailing Twelve Months | 0.02 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.6882 |
| Fifty Day Average Change | 0.3618002 |
| Fifty Day Average Change Percent | 0.047059156 |
| Fifty Two Week Change Percent | -5.952382 |
| Fifty Two Week High | 11.78 |
| Fifty Two Week High Change | -3.7299995 |
| Fifty Two Week High Change Percent | -0.31663835 |
| Fifty Two Week Low | 6.57 |
| Fifty Two Week Low Change | 1.48 |
| Fifty Two Week Low Change Percent | 0.22526635 |
| Fifty Two Week Range | 6.57 - 11.78 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,144,848,600,000 |
| Float Shares | 20,946,520 |
| Forward Eps | 0.06 |
| Forward P E | 134.16667 |
| Free Cashflow | 1,953,875 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 625 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.95355004 |
| Gross Profits | 111,172,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.86694 |
| Held Percent Institutions | 0.03688 |
| Implied Shares Outstanding | 96,333,157 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Dividend Date | 1,673,568,000 |
| Last Dividend Value | 3.6 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,698,710,400 |
| Last Split Factor | 1:15 |
| Long Business Summary | Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc. |
| Long Name | Gyre Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 775,481,984 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_100542295 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 5,027,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 724,120,075 |
| Number Of Analyst Opinions | 3 |
| Open | 8.0 |
| Operating Cashflow | 1,010,000 |
| Operating Margins | 0.0032300001 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 858-567-7770 |
| Previous Close | 7.9 |
| Price Hint | 2 |
| Price To Book | 6.933678 |
| Price To Sales Trailing12 Months | 6.6514735 |
| Profit Margins | 0.043119997 |
| Quick Ratio | 4.579 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.1500001 |
| Regular Market Change Percent | 1.912681 |
| Regular Market Day High | 8.1 |
| Regular Market Day Low | 7.97 |
| Regular Market Day Range | 7.97 - 8.1 |
| Regular Market Open | 8.0 |
| Regular Market Previous Close | 7.9 |
| Regular Market Price | 8.05 |
| Regular Market Time | 1,776,435,806 |
| Regular Market Volume | 16,421 |
| Return On Assets | 0.04927 |
| Return On Equity | 0.082100004 |
| Revenue Growth | 0.334 |
| Revenue Per Share | 1.305 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 91,314,007 |
| Shares Percent Shares Out | 0.0167 |
| Shares Short | 1,525,798 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,344,228 |
| Short Name | Gyre Therapeutics, Inc. |
| Short Percent Of Float | 0.097200006 |
| Short Ratio | 9.99 |
| Source Interval | 15 |
| State | CA |
| Symbol | GYRE |
| Target High Price | 20.0 |
| Target Low Price | 18.0 |
| Target Mean Price | 18.66667 |
| Target Median Price | 18.0 |
| Total Cash | 52,425,000 |
| Total Cash Per Share | 0.574 |
| Total Debt | 939,000 |
| Total Revenue | 116,588,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.02 |
| Trailing P E | 402.50003 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.67705 |
| Two Hundred Day Average Change | 0.37295008 |
| Two Hundred Day Average Change Percent | 0.048579868 |
| Type Disp | Equity |
| Volume | 16,421 |
| Website | https://www.gyretx.com |
| Zip | 92,130 |